Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
- Packer, M.
- McMurray, J.J.V.
- Desai, A.S.
- Gong, J.
- Lefkowitz, M.P.
- Rizkala, A.R.
- Rouleau, J.L.
- Shi, V.C.
- Solomon, S.D.
- Swedberg, K.
- Zile, M.
- Andersen, K.
- Arango, J.L.
- Arnold, J.M.
- B lohlavek, J.
- Bohm, M.
- Boytsov, S.
- Burgess, L.J.
- Cabrera, W.
- Calvo, C.
- Chen, C.-H.
- Dukat, A.
- Duarte, Y.C.
- Erglis, A.
- Fu, M.
- Gomez, E.
- Gonzalez-Medina, A.
- Hagege, A.A.
- Huang, J.
- Katova, T.
- Kiatchoosakun, S.
- Kim, K.-S.
- Kozan, O.
- Llamas, E.B.
- Martinez, F.
- Merkely, B.
- Mendoza, I.
- Mosterd, A.
- Negrusz-Kawecka, M.
- Peuhkurinen, K.
- Ramires, F.J.A.
- Refsgaard, J.
- Rosenthal, A.
- Senni, M.
- Sibulo, A.S.
- Silva-Cardoso, J.
- Squire, I.B.
- Starling, R.C.
- Teerlink, J.R.
- Vanhaecke, J.
- Vinereanu, D.
- Wong, R.C.-C.
DOIAbstract
Background—Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results—We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; h...
Add to ORKG